Martin Aasbrenn
Overview
Explore the profile of Martin Aasbrenn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dworzynski P, Aasbrenn M, Rostgaard K, Melbye M, Gerds T, Hjalgrim H, et al.
Sci Rep
. 2020 Feb;
10(1):1776.
PMID: 32019971
Identification of individuals at risk of developing disease comorbidities represents an important task in tackling the growing personal and societal burdens associated with chronic diseases. We employed machine learning techniques...
12.
Blom-Hogestol I, Aasbrenn M, Chahal-Kummen M, Brunborg C, Eribe I, Kristinsson J, et al.
BMC Gastroenterol
. 2019 Dec;
19(1):204.
PMID: 31791249
Background: Irritable bowel syndrome (IBS) is prevalent in patients with morbid obesity. After Roux-en-Y gastric bypass (RYGB) chronic abdominal pain is common, however the etiology is largely unknown. We aimed...
13.
Aasbrenn M, Farup P, Videm V
Sci Rep
. 2019 Nov;
9(1):17695.
PMID: 31776403
C-reactive protein, neopterin and lactoferrin are biomarkers of atherosclerotic disease. We aimed to assess changes in these biomarkers after conservative and surgical weight loss interventions in individuals with morbid obesity,...
14.
Aasbrenn M, Schnurr T, Have C, Svendstrup M, Hansen D, Worm D, et al.
Obes Surg
. 2019 Apr;
29(8):2554-2561.
PMID: 31001758
Background: The weight loss after bariatric surgery shows considerable individual variation. Twin studies of response to dietary interventions and studies of bariatric surgery patients suggest that genetic differences may play...
15.
Farup P, Aasbrenn M, Valeur J
BMC Obes
. 2018 Dec;
5:30.
PMID: 30524735
Background: Faecal dysbiosis associated with the use of metformin has been conceived as a favourable ("good") dysbiosis and that with intake of non-nutritive sweeteners (NNS) as unfavourable ("bad"). The study...
16.
Aasbrenn M, Lydersen S, Farup P
J Obes
. 2018 Apr;
2018:3732753.
PMID: 29686892
Background: Irritable bowel syndrome (IBS) is common in subjects with morbid obesity; the effect of weight loss programs on bowel symptoms is largely unknown. Methods: This prospective cohort study explored...
17.
Winther R, Aasbrenn M, Farup P
BMC Obes
. 2018 Jan;
4:41.
PMID: 29299330
Background: Subjects with morbid obesity commonly use Non-Nutritive Sweeteners (NNS), but the health-related effects of NNS have been questioned. The objectives of this study were to explore the associations between...
18.
Aasbrenn M, Valeur J, Farup P
Scand J Clin Lab Invest
. 2017 Dec;
78(1-2):109-113.
PMID: 29271246
Biomarkers for irritable bowel syndrome (IBS) are demanded. An altered faecal microbiome has been reported in subjects with IBS and could be a valuable biomarker. This study evaluated the diagnostic...
19.
Aasbrenn M, Raustol A, Bingen H
Nurse Educ Pract
. 2017 Aug;
26:A1-A3.
PMID: 28802671
Participation in a community of practice through asynchronous writing is useful for learning in higher education. We argue that such computer-mediated communication via the internet is valuable in nurse education,...
20.
Kvehaugen A, Aasbrenn M, Farup P
BMC Obes
. 2017 Jul;
4:28.
PMID: 28725447
Background: Baker's/brewer's yeast, , has been used as an alternative to antibiotic growth promoters to improve growth performance in animals. In humans, is among the most commonly detected fungi in...